Alle Targets beginnend mit IL
- IL-1 beta
- IL-10
- IL-10RA
- IL-11
- IL-12/IL-23 p40
- IL-12/IL-35 p35
- IL-13
- IL-15
- IL-17
- IL-17A/F
- IL-18
- IL-19
- IL-2
- IL-20
- IL-21
- IL-22
- IL-24
- IL-25
- IL-26
- IL-27
- IL-28
- IL-3
- IL-3 beta
- IL-31
- IL-32 alpha
- IL-33
- IL-34
- IL-37
- IL-4
- IL-4RA (Dupilumab Biosimilar)
- IL-5
- IL-6
- IL-6 Receptor
- IL-6R (Tocilizumab Biosimilar)
- IL-7
- IL-8
- IL-9
- IL1 Autoantibody
- IL10RB
- IL11RA
- IL12
- IL12 Ab
- IL12A
- IL12B
- IL12RB1
- IL12RB2
- IL13 (Tralokinumab Biosimilar)
- IL13 Receptor alpha 1
- IL13R
- IL13RA2
- IL15RA
- IL16
- IL17 Receptor B
- IL17A (Secukinumab Biosimilar)
- IL17B
- IL17C
- IL17D
- IL17F
- IL17RA
- IL17RA (Brodalumab Biosimilar)
- IL17RC
- IL17RD
- IL17RE
- IL18BP
- IL18R1
- IL18RAP
- IL1A
- IL1A (Bermekimab Biosimilar)
- IL1B (Canakinumab Biosimilar)
- IL1F10
- IL1F9
- IL1R2
- IL1RAP
- IL1RAPL2
- IL1RL1
- IL1RL2
- IL1RN
- IL2 Receptor beta
- IL20 (Fletikumab Biosimilar)
- IL20RA
- IL20RB
- IL21 (Avizakimab Biosimilar)
- IL21 Receptor
- IL22 (Fezakinumab Biosimilar)
- IL22 Ab
- IL22 Receptor alpha 1
- IL22R
- IL22RA2
- IL23
- IL23A
- IL23R
- IL27
- IL27 Receptor alpha
- IL28A
- IL28B
- IL28RA
- IL29
- IL2R
- IL2RA (Basiliximab Biosimilar)
- IL2RA (Daclizumab Biosimilar)
- IL2RG
- IL31RA
- IL32
- IL36A/IL1F6
- IL3RA
- IL4 Receptor
- IL5RA
- IL6 (Siltuximab Biosimilar)
- IL6 Autoantibody
- IL6RA
- IL7R
- IL7RA (Lusvertikimab Biosimilar)
- IL8 Autoantibody
- IL8R
- IL9 (Enokizumab Biosimilar)
- IL9 Receptor
- ILDR1
- ILDR2
- ILF2
- ILK
- ILKAP
- ILL2
- ILL5
- ILP-2
- ILP3
- ILP5
- ILVBL
- ILVC1
- ILVC2
Sie sind hier:
